Interleukin 2 (IL-2) in Melanoma: Anticipating and Managing Toxicities While Optimizing Outcomes

Summary: <p>CME credits: 0.25 Valid until: 03/10/2015 Claim your CME credit at http://www.reachmd.com/cmedetails.aspx?sid=6912</p><p>While responsible for less than 10% of all skin cancers, melanoma is responsible for more than 75% of all skin cancer-related deaths. More than 9,500 people in the U.S. are likely to die from the disease in 2014. Treatment of melanoma is often associated with toxicities based on the agent used. One agent with a long history of managing melanoma is interleukin 2 or IL-2.</p> <p>Join us as Dr. John Kirkwood addresses anticipating and managing toxicity when treating with high-dose IL-2.</p> <p>As of September 4, 2014, the FDA approved Pembrolizumab (Keytruda). This drug won FDA approval for treating advanced or unresectable melanoma in patients not responding to other therapies. This interview may include discussion on this drug or drugs in a related drug class. Please note this updated approval while participating in this activity. To learn more visit: <a href="http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm412802.htm">http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm412802.htm</a></p> <p><strong>Estimated time to complete activity:</strong> 15 minutes</p> <p><img src="../images/cmsimages/CME/project_oncology_257.jpg" border="0" alt="Project Oncology" title="Project Oncology" width="257" height="53"></p>